Key result
Targeting microRNAs with antagomirs offers a potential therapeutic strategy for cardiac disease.
Answers are grounded in this paper and cite their sources.
MicroRNAs (miRNAs) are endogenous, small ribonucleotides regulating the translation of target messenger RNAs that have been shown to be involved in orchestrating growth, development, function, and stress responses of various organs, including the heart. Muscle miRNAs are mainly controlled by a network of myogenic transcription factors, and throughout cardiac development they fine-tune regulatory protein levels in a spatiotemporal manner. Recent profiling studies revealed that miRNA expression patterns are derailed in both human cardiac disease and animal models of cardiac hypertrophy and failure. Modulation of miRNA expression in vitro as well as in vivo has revealed an important role of miRNAs in regulating heart function, particularly cardiac growth and conductance. Here, we overview the recent findings on miRNAs in cardiac development and disease and report the latest advances in the identification and validation of miRNA targets, which are important for a comprehensive understanding of cardiac miRNA function. Finally, we focus on the development and use of miRNA antagonists (antagomirs) to target miRNAs in vivo, which may translate into novel therapeutic strategies for heart disease in the future.
No takes yet. Share an insight, caveat, or question.
Thum et al. (2008) conducted a review in Cardiac hypertrophy, heart failure, and cardiac disease. MicroRNAs and miRNA antagonists (antagomirs) was evaluated. MicroRNAs regulate cardiac growth, development, and conductance, and targeting them in vivo with antagomirs may offer novel therapeutic strategies for heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: